Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05239728




Registration number
NCT05239728
Ethics application status
Date submitted
4/02/2022
Date registered
15/02/2022
Date last updated
25/04/2024

Titles & IDs
Public title
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Scientific title
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
Secondary ID [1] 0 0
MK-6482-022
Secondary ID [2] 0 0
6482-022
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Renal Cell 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Belzutifan
Other interventions - Pembrolizumab
Treatment: Drugs - Placebo

Experimental: Belzutifan + Pembrolizumab - Participants receive belzutifan 120 mg orally once daily (QD) for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks (Q6W) for up to 9 administrations (up to approximately 54 weeks).

Experimental: Placebo + Pembrolizumab - Participants receive placebo orally QD for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once Q6W for up to 9 administrations (up to approximately 54 weeks).


Treatment: Drugs: Belzutifan
Three 40 mg tablets given as a single oral 120 mg dose.

Other interventions: Pembrolizumab
400 mg via IV infusion

Treatment: Drugs: Placebo
Oral tablet
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease-Free Survival (DFS)
Timepoint [1] 0 0
Up to approximately 54 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 89 months
Secondary outcome [2] 0 0
Number of Participants Who Experience at Least One Adverse Event (AE)
Timepoint [2] 0 0
Up to approximately 66 weeks
Secondary outcome [3] 0 0
Number of Participants Who Discontinue Study Treatment Due to an AE
Timepoint [3] 0 0
Up to approximately 54 weeks
Secondary outcome [4] 0 0
Disease Recurrence-Specific Survival 1 (DRSS1)
Timepoint [4] 0 0
Up to approximately 54 months
Secondary outcome [5] 0 0
Disease Recurrence-Specific Survival 2 (DRSS2)
Timepoint [5] 0 0
Up to approximately 54 months
Secondary outcome [6] 0 0
Change From Baseline in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score
Timepoint [6] 0 0
Baseline (Day 1) and up to approximately 36 months
Secondary outcome [7] 0 0
Change From Baseline in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score
Timepoint [7] 0 0
Baseline (Day 1) and up to approximately 36 months
Secondary outcome [8] 0 0
Change From Baseline in Role Functioning Using the EORTC QLQ-C30 Items 6 and 7 Score
Timepoint [8] 0 0
Baseline (Day 1) and up to approximately 36 months
Secondary outcome [9] 0 0
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score
Timepoint [9] 0 0
Baseline (Day 1) and up to approximately 36 months

Eligibility
Key inclusion criteria
The main inclusion and exclusion criteria include but are not limited to the following:



- Has a histologically or cytologically confirmed diagnosis of RCC with clear cell
component per American Joint Committee on Cancer (AJCC) (8th Edition), with or without
sarcomatoid features

- Has intermediate-high risk, high risk, or M1 no evidence of disease (NED) RCC as
defined by the following pathological tumor-node metastasis and tumor grading:

1. Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, any grade,
N0, M0

2. High risk RCC: pT4, any Grade N0, M0; pT any stage, any Grade, N+, M0

3. M1 NED RCC participants who present not only with the primary kidney tumor but
also solid, isolated, soft tissue metastases that can be completely resected at
one of the following: the time of nephrectomy (synchronous) or, =2 years from
nephrectomy (metachronous)

- Has undergone complete resection of the primary tumor (partial or radical nephrectomy)
and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED
participants

- Must have undergone a nephrectomy and/or metastasectomy =12 weeks prior to
randomization

- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10
days before randomization.

- Male participants must agree to continue contraception at least 7 days after the last
dose of belzutifan/placebo

- Female participants of childbearing potential must be willing to use an adequate
method of contraception, for the course of the study through 120 days after the last
dose of pembrolizumab or at least 30 days after last dose of belzutifan/placebo,
whichever occurs last

- Has adequate organ function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has had a major surgery, other than nephrectomy plus resection of preexisting
metastases for M1 NED participants, within 4 weeks prior to randomization

- Has a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen,
or requires chronic supplemental oxygen

- Has clinically significant cardiovascular disease within 6 months from first dose of
study intervention

- Has other clinically significant disorders such as: serious active nonhealing
wound/ulcer/bone fracture; requirement for hemodialysis or peritoneal dialysis

- Has preexisting brain or bone metastatic lesions

- Has received prior systemic therapy for RCC

- Has received prior radiotherapy for RCC

- Has received a live or live-attenuated vaccine within 30 days before the first dose of
study intervention; administration of killed vaccines are allowed

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy

- Has a known additional malignancy (other than RCC treated with nephrectomy and/or
metastasectomy) that is progressing or has required active treatment within the past 3
years

- Has an active autoimmune disease that has required systemic treatment in past 2 years
(i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive
drugs); replacement therapy is allowed

- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease

- Has an active infection, requiring systemic therapy

- Has a known history of human immunodeficiency virus (HIV) infection, a known history
of Hepatitis B or known active Hepatitis C virus infection

- Has had an allogenic tissue/solid organ transplant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/09/2029
Actual
Sample size
Target
1800
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 0002) - Blacktown
Recruitment hospital [2] 0 0
Macquarie University-MQ Health Clinical Trials Unit ( Site 0003) - Macquarie University
Recruitment hospital [3] 0 0
Tamworth Hospital-North West Cancer Centre ( Site 0006) - North Tamworth
Recruitment hospital [4] 0 0
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si - Brisbane
Recruitment hospital [5] 0 0
Lyell McEwin Hospital-Oncology Clinical Trials Unit ( Site 0008) - Elizabeth Vale
Recruitment hospital [6] 0 0
Austin Health-Cancer Clinical Trials Centre ( Site 0005) - Heidelberg
Recruitment hospital [7] 0 0
Fiona Stanley Hospital-Medical Oncology ( Site 0004) - Murdoch
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2109 - Macquarie University
Recruitment postcode(s) [3] 0 0
2340 - North Tamworth
Recruitment postcode(s) [4] 0 0
4029 - Brisbane
Recruitment postcode(s) [5] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Montana
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
South Dakota
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
Brazil
State/province [23] 0 0
Ceara
Country [24] 0 0
Brazil
State/province [24] 0 0
Minas Gerais
Country [25] 0 0
Brazil
State/province [25] 0 0
Parana
Country [26] 0 0
Brazil
State/province [26] 0 0
Rio Grande Do Norte
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio Grande Do Sul
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Paulo
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Pazardzhik
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Sofia (stolitsa)
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Plovdiv
Country [32] 0 0
Canada
State/province [32] 0 0
Alberta
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Chile
State/province [36] 0 0
Araucania
Country [37] 0 0
Chile
State/province [37] 0 0
Los Lagos
Country [38] 0 0
Chile
State/province [38] 0 0
Los Rios
Country [39] 0 0
Chile
State/province [39] 0 0
Region M. De Santiago
Country [40] 0 0
Chile
State/province [40] 0 0
Valparaiso
Country [41] 0 0
Chile
State/province [41] 0 0
Antofagasta
Country [42] 0 0
China
State/province [42] 0 0
Anhui
Country [43] 0 0
China
State/province [43] 0 0
Beijing
Country [44] 0 0
China
State/province [44] 0 0
Chongqing
Country [45] 0 0
China
State/province [45] 0 0
Fujian
Country [46] 0 0
China
State/province [46] 0 0
Guangdong
Country [47] 0 0
China
State/province [47] 0 0
Henan
Country [48] 0 0
China
State/province [48] 0 0
Hubei
Country [49] 0 0
China
State/province [49] 0 0
Hunan
Country [50] 0 0
China
State/province [50] 0 0
Jiangsu
Country [51] 0 0
China
State/province [51] 0 0
Jiangxi
Country [52] 0 0
China
State/province [52] 0 0
Shaanxi
Country [53] 0 0
China
State/province [53] 0 0
Shanghai
Country [54] 0 0
China
State/province [54] 0 0
Sichuan
Country [55] 0 0
China
State/province [55] 0 0
Tianjin
Country [56] 0 0
China
State/province [56] 0 0
Zhejiang
Country [57] 0 0
Colombia
State/province [57] 0 0
Atlantico
Country [58] 0 0
Colombia
State/province [58] 0 0
Cesar
Country [59] 0 0
Colombia
State/province [59] 0 0
Cordoba
Country [60] 0 0
Colombia
State/province [60] 0 0
Distrito Capital De Bogota
Country [61] 0 0
Czechia
State/province [61] 0 0
Brno-mesto
Country [62] 0 0
Czechia
State/province [62] 0 0
Moravskoslezsky Kraj
Country [63] 0 0
Czechia
State/province [63] 0 0
Olomoucky Kraj
Country [64] 0 0
Czechia
State/province [64] 0 0
Praha 4
Country [65] 0 0
Czechia
State/province [65] 0 0
Praha 5
Country [66] 0 0
Czechia
State/province [66] 0 0
Hradec Kralove
Country [67] 0 0
Finland
State/province [67] 0 0
Pirkanmaa
Country [68] 0 0
Finland
State/province [68] 0 0
Pohjois-Pohjanmaa
Country [69] 0 0
Finland
State/province [69] 0 0
Pohjois-Savo
Country [70] 0 0
Finland
State/province [70] 0 0
Uusimaa
Country [71] 0 0
Finland
State/province [71] 0 0
Varsinais-Suomi
Country [72] 0 0
France
State/province [72] 0 0
Alsace
Country [73] 0 0
France
State/province [73] 0 0
Centre
Country [74] 0 0
France
State/province [74] 0 0
Doubs
Country [75] 0 0
France
State/province [75] 0 0
Ile-de-France
Country [76] 0 0
France
State/province [76] 0 0
Ille-et-Vilaine
Country [77] 0 0
France
State/province [77] 0 0
Maine-et-Loire
Country [78] 0 0
France
State/province [78] 0 0
Rhone-Alpes
Country [79] 0 0
France
State/province [79] 0 0
Paris
Country [80] 0 0
Germany
State/province [80] 0 0
Baden-Wurttemberg
Country [81] 0 0
Germany
State/province [81] 0 0
Bayern
Country [82] 0 0
Germany
State/province [82] 0 0
Nordrhein-Westfalen
Country [83] 0 0
Germany
State/province [83] 0 0
Saarland
Country [84] 0 0
Germany
State/province [84] 0 0
Sachsen-Anhalt
Country [85] 0 0
Germany
State/province [85] 0 0
Sachsen
Country [86] 0 0
Germany
State/province [86] 0 0
Thuringen
Country [87] 0 0
Germany
State/province [87] 0 0
Berlin
Country [88] 0 0
Germany
State/province [88] 0 0
Hamburg
Country [89] 0 0
Greece
State/province [89] 0 0
Attiki
Country [90] 0 0
Greece
State/province [90] 0 0
Thessaloniki
Country [91] 0 0
Hungary
State/province [91] 0 0
Csongrad
Country [92] 0 0
Hungary
State/province [92] 0 0
Gyor-Moson-Sopron
Country [93] 0 0
Hungary
State/province [93] 0 0
Pest
Country [94] 0 0
Hungary
State/province [94] 0 0
Somogy
Country [95] 0 0
Hungary
State/province [95] 0 0
Debrecen
Country [96] 0 0
Ireland
State/province [96] 0 0
Dublin
Country [97] 0 0
Ireland
State/province [97] 0 0
Cork
Country [98] 0 0
Israel
State/province [98] 0 0
Be'er Sheva
Country [99] 0 0
Israel
State/province [99] 0 0
Haifa
Country [100] 0 0
Israel
State/province [100] 0 0
Jerusalem
Country [101] 0 0
Israel
State/province [101] 0 0
Petah-Tikva
Country [102] 0 0
Israel
State/province [102] 0 0
Ramat Gan
Country [103] 0 0
Israel
State/province [103] 0 0
Tel Aviv
Country [104] 0 0
Italy
State/province [104] 0 0
Emilia-Romagna
Country [105] 0 0
Italy
State/province [105] 0 0
Lazio
Country [106] 0 0
Italy
State/province [106] 0 0
Lombardia
Country [107] 0 0
Italy
State/province [107] 0 0
Piemonte
Country [108] 0 0
Italy
State/province [108] 0 0
Puglia
Country [109] 0 0
Italy
State/province [109] 0 0
Toscana
Country [110] 0 0
Italy
State/province [110] 0 0
Arezzo
Country [111] 0 0
Italy
State/province [111] 0 0
Bologna
Country [112] 0 0
Italy
State/province [112] 0 0
Terni
Country [113] 0 0
Japan
State/province [113] 0 0
Aichi
Country [114] 0 0
Japan
State/province [114] 0 0
Chiba
Country [115] 0 0
Japan
State/province [115] 0 0
Ehime
Country [116] 0 0
Japan
State/province [116] 0 0
Hokkaido
Country [117] 0 0
Japan
State/province [117] 0 0
Kanagawa
Country [118] 0 0
Japan
State/province [118] 0 0
Nara
Country [119] 0 0
Japan
State/province [119] 0 0
Osaka
Country [120] 0 0
Japan
State/province [120] 0 0
Shizuoka
Country [121] 0 0
Japan
State/province [121] 0 0
Tokyo
Country [122] 0 0
Japan
State/province [122] 0 0
Toyama
Country [123] 0 0
Japan
State/province [123] 0 0
Fukuoka
Country [124] 0 0
Japan
State/province [124] 0 0
Kagoshima
Country [125] 0 0
Japan
State/province [125] 0 0
Kumamoto
Country [126] 0 0
Japan
State/province [126] 0 0
Okayama
Country [127] 0 0
Japan
State/province [127] 0 0
Wakayama
Country [128] 0 0
Korea, Republic of
State/province [128] 0 0
Kyonggi-do
Country [129] 0 0
Korea, Republic of
State/province [129] 0 0
Seoul
Country [130] 0 0
Malaysia
State/province [130] 0 0
Kuala Lumpur
Country [131] 0 0
Malaysia
State/province [131] 0 0
Pulau Pinang
Country [132] 0 0
Malaysia
State/province [132] 0 0
Sarawak
Country [133] 0 0
Mexico
State/province [133] 0 0
Distrito Federal
Country [134] 0 0
Mexico
State/province [134] 0 0
Jalisco
Country [135] 0 0
Mexico
State/province [135] 0 0
Nuevo Leon
Country [136] 0 0
Mexico
State/province [136] 0 0
Queretaro
Country [137] 0 0
Mexico
State/province [137] 0 0
Sinaloa
Country [138] 0 0
Mexico
State/province [138] 0 0
Oaxaca
Country [139] 0 0
Mexico
State/province [139] 0 0
Puebla
Country [140] 0 0
Netherlands
State/province [140] 0 0
Gelderland
Country [141] 0 0
Netherlands
State/province [141] 0 0
Limburg
Country [142] 0 0
Netherlands
State/province [142] 0 0
Noord-Brabant
Country [143] 0 0
Netherlands
State/province [143] 0 0
Noord-Holland
Country [144] 0 0
Netherlands
State/province [144] 0 0
Overijssel
Country [145] 0 0
Netherlands
State/province [145] 0 0
Zuid-Holland
Country [146] 0 0
Netherlands
State/province [146] 0 0
Groningen
Country [147] 0 0
Netherlands
State/province [147] 0 0
Utrecht
Country [148] 0 0
New Zealand
State/province [148] 0 0
Auckland
Country [149] 0 0
Poland
State/province [149] 0 0
Dolnoslaskie
Country [150] 0 0
Poland
State/province [150] 0 0
Kujawsko-pomorskie
Country [151] 0 0
Poland
State/province [151] 0 0
Malopolskie
Country [152] 0 0
Poland
State/province [152] 0 0
Mazowieckie
Country [153] 0 0
Poland
State/province [153] 0 0
Podkarpackie
Country [154] 0 0
Poland
State/province [154] 0 0
Wielkopolskie
Country [155] 0 0
Poland
State/province [155] 0 0
Zachodniopomorskie
Country [156] 0 0
Romania
State/province [156] 0 0
Bucuresti
Country [157] 0 0
Romania
State/province [157] 0 0
Cluj
Country [158] 0 0
Romania
State/province [158] 0 0
Dolj
Country [159] 0 0
Romania
State/province [159] 0 0
Ilfov
Country [160] 0 0
Romania
State/province [160] 0 0
Timis
Country [161] 0 0
Singapore
State/province [161] 0 0
Central Singapore
Country [162] 0 0
Singapore
State/province [162] 0 0
South West
Country [163] 0 0
Spain
State/province [163] 0 0
Gerona
Country [164] 0 0
Spain
State/province [164] 0 0
Madrid, Comunidad De
Country [165] 0 0
Spain
State/province [165] 0 0
Valenciana, Comunitat
Country [166] 0 0
Spain
State/province [166] 0 0
Barcelona
Country [167] 0 0
Spain
State/province [167] 0 0
Lugo
Country [168] 0 0
Spain
State/province [168] 0 0
Madrid
Country [169] 0 0
Spain
State/province [169] 0 0
Malaga
Country [170] 0 0
Sweden
State/province [170] 0 0
Stockholms Lan
Country [171] 0 0
Sweden
State/province [171] 0 0
Uppsala Lan
Country [172] 0 0
Sweden
State/province [172] 0 0
Vastra Gotalands Lan
Country [173] 0 0
Taiwan
State/province [173] 0 0
Kaohsiung
Country [174] 0 0
Taiwan
State/province [174] 0 0
Taipei
Country [175] 0 0
Taiwan
State/province [175] 0 0
Taichung
Country [176] 0 0
Taiwan
State/province [176] 0 0
Taoyuan
Country [177] 0 0
Thailand
State/province [177] 0 0
Krung Thep Maha Nakhon
Country [178] 0 0
Thailand
State/province [178] 0 0
Songkhla
Country [179] 0 0
Turkey
State/province [179] 0 0
Ankara
Country [180] 0 0
Turkey
State/province [180] 0 0
Istanbul
Country [181] 0 0
Turkey
State/province [181] 0 0
Adana
Country [182] 0 0
Turkey
State/province [182] 0 0
Izmir
Country [183] 0 0
United Kingdom
State/province [183] 0 0
England
Country [184] 0 0
United Kingdom
State/province [184] 0 0
Glasgow City
Country [185] 0 0
United Kingdom
State/province [185] 0 0
Hammersmith And Fulham
Country [186] 0 0
United Kingdom
State/province [186] 0 0
London, City Of
Country [187] 0 0
United Kingdom
State/province [187] 0 0
Wales

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482)
plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the
adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.

The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo
plus pembrolizumab with respect to disease-free survival (DFS).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05239728
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries